“Guided by insights from our second quarter underperformance and building on our long-term vision, we are evolving our commercial approach to re-direct more of our focus toward supporting customer success within new and existing practices,” said Ron Kurtz, CEO and president of RxSight (RXST). “By deepening our engagement with our clinical partners, we believe we will be better positioned to ensure they can fully realize the benefits of adjustability and achieve the superior outcomes for their patients that ultimately drive further LAL adoption.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight Re-elects Directors at Annual Meeting
- RxSight’s Positive Momentum and Strategic Growth Initiatives Support Buy Rating
- Down Over 30%: Wells Fargo Says Now Is the Time to Load Up on These 2 Beaten-Down Stocks
- Netflix, Reddit downgraded: Wall Street’s top analyst calls
- RxSight’s Promising Market Position and Growth Potential: A Buy Recommendation by Larry Biegelsen